Literature DB >> 16436933

Why do we need new and better antidepressants?

Stuart A Montgomery1.   

Abstract

The range of available antidepressants is reviewed in relation to mechanisms of action and the evidence of efficacy in general and efficacy in severe depression in particular. In studies investigating efficacy in major depressive disorder, not all antidepressants have been shown to have clear-cut efficacy in severe depression. Here, the minimum standards for the necessary methodology to investigate efficacy in severe depression are reviewed and the methods that are needed to establish efficacy as a superior antidepressant or as an antidepressant with a faster than expected response are suggested. A review of the mechanisms of action of different antidepressants is accompanied by a critical review of the properties of an antidepressant likely to achieve either efficacy in severe depression or the status of a superior antidepressant.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16436933     DOI: 10.1097/01.yic.0000199455.39552.1c

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  8 in total

1.  Alterations in the neuropeptide galanin system in major depressive disorder involve levels of transcripts, methylation, and peptide.

Authors:  Swapnali Barde; Joelle Rüegg; Josée Prud'homme; Tomas J Ekström; Miklos Palkovits; Gustavo Turecki; Gyorgy Bagdy; Robert Ihnatko; Elvar Theodorsson; Gabriella Juhasz; Rochellys Diaz-Heijtz; Naguib Mechawar; Tomas G M Hökfelt
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-09       Impact factor: 11.205

2.  Effects of overnight sleep restriction on brain chemistry and mood in women with unipolar depression and healthy controls.

Authors:  Denise Bernier; Robert Bartha; Sivakumaran Devarajan; Frank P Macmaster; Matthias H Schmidt; Benjamin Rusak
Journal:  J Psychiatry Neurosci       Date:  2009-09       Impact factor: 6.186

3.  Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study.

Authors:  Michele Fornaro; Michael J McCarthy; Domenico De Berardis; Concetta De Pasquale; Massimo Tabaton; Matteo Martino; Salvatore Colicchio; Carlo Ignazio Cattaneo; Emanuela D'Angelo; Pantaleo Fornaro
Journal:  Neuropsychiatr Dis Treat       Date:  2013-02-15       Impact factor: 2.570

4.  Resting-state functional connectivity bias of middle temporal gyrus and caudate with altered gray matter volume in major depression.

Authors:  Chaoqiong Ma; Jurong Ding; Jun Li; Wenbin Guo; Zhiliang Long; Feng Liu; Qing Gao; Ling Zeng; Jingping Zhao; Huafu Chen
Journal:  PLoS One       Date:  2012-09-24       Impact factor: 3.240

5.  Emotional memory impairments in a genetic rat model of depression: involvement of 5-HT/MEK/Arc signaling in restoration.

Authors:  T M Eriksson; P Delagrange; M Spedding; M Popoli; A A Mathé; S O Ögren; P Svenningsson
Journal:  Mol Psychiatry       Date:  2011-01-18       Impact factor: 15.992

6.  Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.

Authors:  Paula L Jacobsen; Linda Harper; Lambros Chrones; Serena Chan; Atul R Mahableshwarkar
Journal:  Int Clin Psychopharmacol       Date:  2015-09       Impact factor: 1.659

7.  Differentiating Melancholic and Non-melancholic Major Depressive Disorder Using Fractional Amplitude of Low-Frequency Fluctuations.

Authors:  Yingying Zhang; Xilong Cui; Yangpan Ou; Feng Liu; Huabing Li; Jindong Chen; Jingping Zhao; Guangrong Xie; Wenbin Guo
Journal:  Front Psychiatry       Date:  2022-02-02       Impact factor: 4.157

Review 8.  Agomelatine: efficacy at each phase of antidepressant treatment.

Authors:  Sidney H Kennedy
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.